Already approved BCMA-targeting chimeric antigen receptor T-cell therapeutic Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and bluebird bio has an eight-month head start over Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s pending ciltacabtagene autoleucel (cilta-cel), but updated pivotal trial data for cilta-cel show response rates that could give the runner-up an advantage in the multiple myeloma market.
Janssen and Legend’s B-cell maturation antigen (BCMA)-targeting CAR-T therapy cilta-cel is under priority review at the US Food and Drug...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)